{"id":20844,"date":"2023-10-30T14:29:51","date_gmt":"2023-10-30T13:29:51","guid":{"rendered":"https:\/\/ggba.swiss\/?p=20844"},"modified":"2023-10-30T14:29:52","modified_gmt":"2023-10-30T13:29:52","slug":"bactheras-visp-plant-aims-to-revolutionize-microbiome-based-treatments","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/bactheras-visp-plant-aims-to-revolutionize-microbiome-based-treatments\/","title":{"rendered":"Bacthera’s Visp plant aims to revolutionize microbiome-based treatments"},"content":{"rendered":"\n

Bacthera<\/a>, a leading Contract Development and Manufacturing Organization (CDMO), specializes in the advancement of microbiome-based therapies. With a focus on producing treatments that target the human microbiome, the company combines expertise and modern facilities to address a range of health challenges, emphasizing individualized patient care and innovative solutions.<\/p>\n\n\n\n

Based in Visp (canton of Valais), Bacthera’s Center of Excellence, dubbed MC4a, exemplifies a landmark commitment to producing groundbreaking microbiome-based treatments. Foremost among these is SER-109, a product of Seres Therapeutics<\/a>, which aims to combat the recurrence of the perilous Clostridioides difficile infection (rCDI). This infection, typically an aftermath of antibiotic treatments, triggers life-threatening diarrhea.<\/p>\n\n\n\n

Lukas Sch\u00fcpbach, CEO of Bacthera, explained: “With our new Microbiome Center of Excellence in Visp, we look forward to supporting the manufacture of life-saving microbiome-based therapies such as SER-109.” His sentiments were echoed by Eric Shaff, the CEO of Seres Therapeutics, who emphasized the significance of partnering with Bacthera to amplify the production of SER-109 to cater to surging demand.<\/p>\n\n\n\n

Bacthera and Seres Therapeutics\u2019 collaboration started two years ago with the noble vision of manufacturing SER-109. Thomas Steinmann, overseeing the Visp site, encapsulated the ongoing progress, saying: \u201cEvery day, machines vital to the future commercial production of VOWST\u2122 (fecal microbiota spores, live-brpk) are set up and then qualified. Our expert team in Visp is transitioning seamlessly into this new environment, preparing for process performance qualification.\u201d<\/p>\n\n\n\n

A hub of excellence in microbiome treatments<\/h4>\n\n\n\n

The crux of the agreement between Bacthera and Seres Therapeutics is to expand Seres’ commercial manufacturing horizons. With Bacthera’s involvement, SER-109 stands to gain a boost in its commercial production potential, positioning it as possibly the pioneer product in the living biotherapeutics realm to be commercially produced.<\/p>\n\n\n\n

Safeguarded within Lonza’s Visp industry park, Bacthera\u2019s MC4a spans 12,000 square meters. It houses three distinct manufacturing floors, one of which will exclusively cater to SER-109 production. This initiative leans heavily on the tried-and-true Lonza Ibex Solutions concept<\/a>, ensuring early commercial launches and seamless production.<\/p>\n\n\n\n

Elaborating on the importance of the collaboration, Jean-Christophe Hyvert, President of Biological Products and Cells & Genes at Lonza, commented: \u201cThis collaboration truly illustrates Bacthera\u2019s leading LBP manufacturing offering as a strategic partner on the road to commercialization. Bacthera will use a facility inspired by Ibex solutions to offer flexibility, speed, and assured supply, ushering in a pivotal moment in the progression of microbiome-targeted therapies.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"

In Visp, Bacthera\u2019s MC4a Center of Excellence readies to manufacture transformative microbiome therapies, notably the Seres Therapteutics\u2019 life-saving SER-109.<\/p>\n","protected":false},"author":6,"featured_media":20845,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[833],"tags":[912,929,911,901],"class_list":["post-20844","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science","tag-biotech","tag-manufacturing","tag-pharma","tag-technology-park"],"acf":[],"yoast_head":"\nBacthera's Visp plant to revolutionize microbiome-based treatments<\/title>\n<meta name=\"description\" content=\"In Visp, CDMO Bacthera\u2019s MC4a Center of Excellence readies to manufacture transformative microbiome therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/en\/bactheras-visp-plant-aims-to-revolutionize-microbiome-based-treatments\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bacthera's Visp plant to revolutionize microbiome-based treatments\" \/>\n<meta property=\"og:description\" content=\"In Visp, CDMO Bacthera\u2019s MC4a Center of Excellence readies to manufacture transformative microbiome therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/en\/bactheras-visp-plant-aims-to-revolutionize-microbiome-based-treatments\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-30T13:29:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-10-30T13:29:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Bacthera_Visp-1180x811-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/en\/bactheras-visp-plant-aims-to-revolutionize-microbiome-based-treatments\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/en\/bactheras-visp-plant-aims-to-revolutionize-microbiome-based-treatments\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Bacthera’s Visp plant aims to revolutionize microbiome-based treatments\",\"datePublished\":\"2023-10-30T13:29:51+00:00\",\"dateModified\":\"2023-10-30T13:29:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/bactheras-visp-plant-aims-to-revolutionize-microbiome-based-treatments\/\"},\"wordCount\":408,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/bactheras-visp-plant-aims-to-revolutionize-microbiome-based-treatments\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Bacthera_Visp-1180x811-1.jpg\",\"keywords\":[\"Biotech\",\"Manufacturing\",\"Pharma\",\"Technology Park\"],\"articleSection\":[\"Life sciences\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/en\/bactheras-visp-plant-aims-to-revolutionize-microbiome-based-treatments\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/en\/bactheras-visp-plant-aims-to-revolutionize-microbiome-based-treatments\/\",\"url\":\"https:\/\/ggba.swiss\/en\/bactheras-visp-plant-aims-to-revolutionize-microbiome-based-treatments\/\",\"name\":\"Bacthera's Visp plant to revolutionize microbiome-based treatments\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/bactheras-visp-plant-aims-to-revolutionize-microbiome-based-treatments\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/bactheras-visp-plant-aims-to-revolutionize-microbiome-based-treatments\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Bacthera_Visp-1180x811-1.jpg\",\"datePublished\":\"2023-10-30T13:29:51+00:00\",\"dateModified\":\"2023-10-30T13:29:52+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"In Visp, CDMO Bacthera\u2019s MC4a Center of Excellence readies to manufacture transformative microbiome therapies.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/en\/bactheras-visp-plant-aims-to-revolutionize-microbiome-based-treatments\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/en\/bactheras-visp-plant-aims-to-revolutionize-microbiome-based-treatments\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ggba.swiss\/en\/bactheras-visp-plant-aims-to-revolutionize-microbiome-based-treatments\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Bacthera_Visp-1180x811-1.jpg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Bacthera_Visp-1180x811-1.jpg\",\"width\":1180,\"height\":811,\"caption\":\"Located in Lonza's Visp industry park, Bacthera's MC4a Center of Excellence covers 12,000 square meters, featuring three manufacturing floors with one dedicated to SER-109 production. | \u00a9 Bacthera\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/en\/bactheras-visp-plant-aims-to-revolutionize-microbiome-based-treatments\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bacthera’s Visp plant aims to revolutionize microbiome-based treatments\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bacthera's Visp plant to revolutionize microbiome-based treatments","description":"In Visp, CDMO Bacthera\u2019s MC4a Center of Excellence readies to manufacture transformative microbiome therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/en\/bactheras-visp-plant-aims-to-revolutionize-microbiome-based-treatments\/","og_locale":"en_US","og_type":"article","og_title":"Bacthera's Visp plant to revolutionize microbiome-based treatments","og_description":"In Visp, CDMO Bacthera\u2019s MC4a Center of Excellence readies to manufacture transformative microbiome therapies.","og_url":"https:\/\/ggba.swiss\/en\/bactheras-visp-plant-aims-to-revolutionize-microbiome-based-treatments\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2023-10-30T13:29:51+00:00","article_modified_time":"2023-10-30T13:29:52+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Bacthera_Visp-1180x811-1.jpg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pierre-Yves Oehrli","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/en\/bactheras-visp-plant-aims-to-revolutionize-microbiome-based-treatments\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/en\/bactheras-visp-plant-aims-to-revolutionize-microbiome-based-treatments\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Bacthera’s Visp plant aims to revolutionize microbiome-based treatments","datePublished":"2023-10-30T13:29:51+00:00","dateModified":"2023-10-30T13:29:52+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/en\/bactheras-visp-plant-aims-to-revolutionize-microbiome-based-treatments\/"},"wordCount":408,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/en\/bactheras-visp-plant-aims-to-revolutionize-microbiome-based-treatments\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Bacthera_Visp-1180x811-1.jpg","keywords":["Biotech","Manufacturing","Pharma","Technology Park"],"articleSection":["Life sciences"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/en\/bactheras-visp-plant-aims-to-revolutionize-microbiome-based-treatments\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/en\/bactheras-visp-plant-aims-to-revolutionize-microbiome-based-treatments\/","url":"https:\/\/ggba.swiss\/en\/bactheras-visp-plant-aims-to-revolutionize-microbiome-based-treatments\/","name":"Bacthera's Visp plant to revolutionize microbiome-based treatments","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/en\/bactheras-visp-plant-aims-to-revolutionize-microbiome-based-treatments\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/en\/bactheras-visp-plant-aims-to-revolutionize-microbiome-based-treatments\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Bacthera_Visp-1180x811-1.jpg","datePublished":"2023-10-30T13:29:51+00:00","dateModified":"2023-10-30T13:29:52+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"In Visp, CDMO Bacthera\u2019s MC4a Center of Excellence readies to manufacture transformative microbiome therapies.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/en\/bactheras-visp-plant-aims-to-revolutionize-microbiome-based-treatments\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/en\/bactheras-visp-plant-aims-to-revolutionize-microbiome-based-treatments\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ggba.swiss\/en\/bactheras-visp-plant-aims-to-revolutionize-microbiome-based-treatments\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Bacthera_Visp-1180x811-1.jpg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Bacthera_Visp-1180x811-1.jpg","width":1180,"height":811,"caption":"Located in Lonza's Visp industry park, Bacthera's MC4a Center of Excellence covers 12,000 square meters, featuring three manufacturing floors with one dedicated to SER-109 production. | \u00a9 Bacthera"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/en\/bactheras-visp-plant-aims-to-revolutionize-microbiome-based-treatments\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"Bacthera’s Visp plant aims to revolutionize microbiome-based treatments"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/20844","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=20844"}],"version-history":[{"count":2,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/20844\/revisions"}],"predecessor-version":[{"id":20849,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/20844\/revisions\/20849"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/20845"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=20844"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=20844"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=20844"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}